Promising Experimental Drug to Watch

Options
Bestbird
Bestbird Member Posts: 2,818

Here's an interesting experimental drug to watch if your cancer is HER2 positive or HER2 low (IHC 2+ or IHC 1+). It has been written up in my book, "The Insider's Guide to Metastatic Breast Cancer" which is available in paperback and eBook formats as well as in a complimentary .pdf. If interested, please visit https://www.insidersguidembc.com

The recent Phase 2 DESTINY BreastO1 clinical trial studied the experimental drug trastuzumab deruxtecan in 115 patients with unresectable and/or metastatic cancer who had previously received a median 7 lines of therapy including Herceptin and Kadcyla (as well as Perjeta in most cases). The patients in the study had either: HER2-positive breast cancer, HER2–low expressing breast cancer (considered HER2 negative), HER2-positive gastric cancer, or various other HER2-expressing solid tumors.
Data revealed that the overall response rate with trastuzumab deruxtecan was 59.5% and the disease control rate was an impressive 93.7%. The median duration of response was 20.7 months, the median progression-free survival was 22.1 months, and the median overall survival has not yet been reached.

From: https://www.targetedonc.com/news/fam-trastuzumab-deruxtecan-demonstrates-encouraging-responses-in-advanced-her2-breast-cancer As of May 2019, there are three recruiting clinical trials of trastuzumab deruxtecan for MBC patients.

Comments

  • vlnrph
    vlnrph Member Posts: 1,632
    edited May 2019

    I am glad to know that studies like this are taking place among the heavily pre-treated.

  • SchnauzerMom
    SchnauzerMom Member Posts: 374
    edited May 2019

    Wow! Sounds very promising! Good to hear this.

  • nanette7fl
    nanette7fl Member Posts: 469
    edited May 2019

    I'm on Kadcyla. It's for women who have residual cancer after neo-adjuvant chemotherapy. I had tumors in my Sentinal nodes that were found during my MX but weren't there during my breast MRI 3 weeks earlier and 1 tumor that reduced during Taxol/Herceptin to 3 residual tumors classified me.

  • Meja
    Meja Member Posts: 102
    edited May 2019

    Very promising.

    Thank you for posting.

  • ann273
    ann273 Member Posts: 209
    edited August 2019

    Has anyone on BCO been on DS-2801? Ive seen stories on inspire and it really seems to be working well for many people with response times between 7 months to 22 months which is great for stage 4 MBC. I've been following it and it looks like its a phase 3 trial and they're going to apply for FDA approval soon. Considering it works for low HEr2 expression it would cover a lot of us.

  • LoriCA
    LoriCA Member Posts: 923
    edited August 2019

    My caution about this drug is that so far in trials it has had a 50% rate of Grade 3 or higher Adverse Events (for breast cancer; it was 64% in I think gastro), 22..9% had a serious (life-threatening) Adverse Event and the drug has directly caused 5 deaths so far. The rate of Interstitial Lung Disease has been so high it required an outside independent agency to monitor for the duration of the trials.

    I once experienced a Grade 3+ Adverse Event (on a different drug) that made me so miserable I told my oncologist I would rather die. The risk is too high for me on this drug, and I really have a hard time trying to understand why nobody cares how toxic it is. We need to demand better than this!

    I've had some people ask me where I got this information - most of it is right in the press releases on the company's website, the rest is in the Phase I and II trial results.

  • ann273
    ann273 Member Posts: 209
    edited August 2019

    Hi Lori, its disappointing to hear that about the adverse events :( It seems to have a pretty good response rate and I was hoping that its approval means we'll have another tool in our arsenal. I hope they figure out dosages and how to manage side effects. Unfortunately there comes a point for us where we dont have a choice..

  • LoriCA
    LoriCA Member Posts: 923
    edited August 2019

    ann723, I believe that we always have a choice. We may each have different priorities along the Quality of Life vs Quantity of Life continuum, but we always have a choice. The first thing my oncologist brings up when we are evaluating treatment choices is the risk vs potential benefit so I can make an informed decision, and he's not afraid to tell me when he believes the risk (of toxicity) outweighs the potential benefit. And I understand it means that at some point I will have no acceptable options left.

    Some noted oncologists have been very vocal recently about the unacceptable level of toxicity for recent drug approvals, and they've been leading some very enlightening conversations on social media. Several have stated that a rate above 10% for AEs Grade 3 and higher is unacceptable. Grade 3 is "severe, but not immediately life threatening", Grade 4 is life threatening, Grade 5 is death from the AE. Having already experienced a Grade 3+ AE that made me wish I was dead, a 50% chance that I would go through that experience again is too high for me, it's no deal. I don't want to stay alive only to be that miserable. But I understand that others may feel differently.

    Something similar happened when capecitabine was first approved. The original approved dosage was so toxic that people refused to take it. A few years later we learned that a dosage that was half the amount originally approved was just as effective and drastically reduced the rate and severity of Adverse Events.

    There needs to be more focus in the early trial phases of minimum effective dosage rather than maximum "tolerated" dosage. Even after a rate 50% Grade 3 and higher and several deaths due directly to the drug, they state that they never reached a dose-limiting level of toxicity!

    Anyway, so far it's only been trialed as a third line treatment for HER2+, after Herceptin and Kadcyla have failed. They just started the first trial for HER2-low (DESTINY-Breast04).

    My personal opinion is that they won't let anything get in the way of accelerated approval for this drug because they have almost US$7 billion riding on it.

  • ann273
    ann273 Member Posts: 209
    edited August 2019

    Totally understand that it depends on each person. I'm on Xeloda right now and I have no idea how people tolerated higher dosages. Quality of life is very important to me. I still work full time and want to continue to do so as long as I can. I cant help but want quantity of life too (As I'm sure everyone does). Im only 33 and have been fighting this disease for 6 years now. Sometimes I feel desperate and hopeful that if I up with QOL issues something new will come up that will be my ticket out of this. I know its unrealistic, but one can only hope.

Categories